Debu Tripathy, MD
The treatment paradigm for the neoadjuvant setting of HER2-positive breast cancer continues to evolve, offering new opportunities to improve patient outcomes, according to Debu Tripathy, MD.
(MBCC), Tripathy, a professor and chairman in the Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.
OncLive: Please provide an update on neoadjuvant treatment strategies in HER2-positive breast cancer.
The use of neoadjuvant therapy for HER2-positive breast cancer is an area of increasing understanding, knowledge, and interest. We know that patients clearly achieve a higher chance of a pCR with the addition of trastuzumab to standard chemotherapy. This occurs in both the neoadjuvant and adjuvant settings, which had led to it being the standard of care.
... to read the full story